BMS to Expand Access to Reyataz in Brazil

Bristol-Myers Squibb (BMS) will expand access to its HIV drug Reyataz (atazanavir) in Brazil, according to a BMS statement.

The pharmaceutical company has signed a technology transfer agreement with the Brazilian Ministry of Health, which will enable the Brazilian government to locally manufacture and distribute 200 mg and 300 mg capsules of Reyataz.

To read the BMS statement, visit: http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20111111005380/en&t=634566935118235831.

The Friends of AIDS Foundation is dedicated to enhancing the quality of life for HIV positive individuals and empowering people to make healthy choices to prevent the spread of the HIV virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.

TOGETHER WE REMAIN STRONG!